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Abstract
Objective—Belimumab (Benlysta) is a human monoclonal antibody that inhibits soluble B-
lymphocyte stimulator and was approved by the FDA for treatment of adults with systemic lupus 
erythematosus (SLE). This study evaluates the use and efficacy of belimumab in academic SLE 
practices.
Corresponding author: Anca Askanase, MD, MPH, Division of Adult Rheumatology, New York Presbyterian Hospital, Columbia 
University Medical Center, 630 W 168th St, P&S Building, 10th floor, New York, NY 10032, Tel: 212.342.3684; Fax: 212.342.0509, 
ada20@cumc.columbia.edu. 
Disclosures and funding: This work was supported by an investigator-initiated award to the Systemic Lupus Erythematosus 
International Collaborating Clinics from Glaxo-Smith-Kline. Joyce S Hui-Yuen is the recipient of a T32 Medical Genetics training 
grant from the National Institutes of Health. Anca D Askanase is a consultant for Glaxo Smith Kline (< $10,000 in the past 12 
months), and Michelle Petri has consulted for Glaxo Smith Kline in the past.
HHS Public Access
Author manuscript
J Rheumatol. Author manuscript; available in PMC 2016 December 01.
Published in final edited form as:
J Rheumatol. 2015 December ; 42(12): 2288–2295. doi:10.3899/jrheum.150470.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Methods—Invitations to participate and complete a one-page questionnaire for each patient 
prescribed belimumab were sent to 16 physicians experienced in SLE Phase III clinical trials. The 
outcome was defined as the physician’s impression of improvement in the initial manifestation(s) 
being treated without worsening in other organ systems.
Results—Of 195 patients treated with belimumab at 10 academic centers, 96% were on 
background medications for SLE at initiation of belimumab, with 74% on corticosteroids. The 
main indications for initiation of belimumab were arthritis, rash, and/or worsening serologic 
activity, with 30% of patients unable to taper corticosteroids. Of the 120 patients on belimumab for 
at least 6 months, 51% responded clinically and 67% had ≥25% improvement in laboratory values. 
While numbers are limited, black patients showed improvement at 6 months. In a subset of 39 
patients with childhood-onset SLE, 65% responded favorably at 6 months, and 35% discontinued 
corticosteroids.
Conclusion—Our data demonstrate favorable clinical and laboratory outcomes in patients with 
SLE at 6 months across all racial and ethnic groups, with similar improvement seen among 
patients with childhood-onset SLE.
Keywords
belimumab; lupus treatment; childhood-onset lupus
INTRODUCTION
Systemic lupus erythematosus (SLE) is a chronic, multi-system, autoimmune disease of 
unknown etiology with a heterogeneous range of clinical and serological manifestations. 
Adding to the complexity of SLE is the unpredictability of flares, or periods of increased 
inflammatory disease activity, as well as the accrual of organ damage (1, 2). “Standard of 
care” therapy for SLE includes antimalarials, corticosteroids, immunosuppressives, and 
cytotoxic agents. These treatments often result in undesired long-term adverse effects and 
organ damage that are unavoidable due to the essential role of these medications in SLE 
treatment.
Although the etiology of SLE remains largely unknown, an increased understanding of its 
immunopathogenesis, in particular, B cell-specific mechanisms, has allowed for a focus on 
targeted immunotherapy. This led to the development and testing of belimumab (Benlysta®) 
for SLE and subsequent approval in 2011 by the US Food and Drug Administration for the 
treatment of adults with active SLE (3). Belimumab is a fully-human, recombinant inhibitor 
of soluble B lymphocyte stimulator (BLyS) and neutralizes a key cytokine that plays a major 
role in B cell differentiation, proliferation, and survival (4–6). Two randomized, double-
blind, placebo-controlled, multi-center Phase III trials (BLISS-52 and BLISS-76) 
demonstrated improvement in disease activity in patients treated with belimumab and 
standard of care SLE therapy compared to those treated with placebo and standard therapy 
alone (7, 8).
Since the initial belimumab clinical trials, the post-approval clinical experience of patients 
receiving belimumab at 10mg/kg/dose every 4 weeks along with standard SLE therapy as 
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well as the practice patterns of academic physicians in clinical settings has received 
increased attention. In addition, the data are scarce on the use of belimumab in patients with 
childhood-onset SLE. Childhood-onset is diagnosed prior to the patient’s 18th birthday and 
accounts for up to 20% of all SLE patients (9). When compared to adult-onset SLE, 
childhood-onset SLE has increased disease activity, morbidity, and mortality, often requiring 
earlier and more aggressive treatment with immunosuppressive medications for disease 
control (10–16).
Due to the multitude of challenging characteristics of successful trials, including identifying 
meaningful outcomes and appropriate patient populations, post-marketing observational 
studies are often useful in providing supplementary information to trials. The objective of 
this multi-center study was to analyze the experience with belimumab in academic clinical 
practices.
MATERIALS AND METHODS
Study Design
This is a prospective, multicenter, observational study conducted in 10 large academic SLE 
clinical practices, 9 of whom were in the United States. Approvals to conduct this study 
were obtained from the Institutional Review Boards of the respective institutions. Sixteen 
adult rheumatologists experienced in Phase III SLE clinical trials were invited to participate, 
10 of whom accepted the invitation and completed repeat assessments of SLE patients 
treated with belimumab as part of their standard of care. Assessments consisted of a single-
page questionnaire per patient completed every three months. All investigators who agreed 
to participate were located in countries where belimumab has received regulatory agency 
approval (United States and Sweden).
Inclusion and exclusion criteria
All patients were required to have a diagnosis of SLE, have met at least 4 of 11 American 
College of Rheumatology (ACR) or Systemic Lupus International Collaborative Clinics 
(SLICC) classification criteria (17, 18), and have started treatment with belimumab after 
approval by regulatory agencies. Exclusion criteria included patients who had previously 
participated in the belimumab clinical trials, and those who met fewer than 4 ACR 
classification criteria. We also excluded patients from this study who had severe renal or 
neuropsychiatric involvement.
Questionnaire
The single-page questionnaire included basic demographic information (e.g., age, sex, race/
ethnicity), SLE data (including disease duration, year of diagnosis, serologies, clinical 
manifestation(s) of lupus, and concomitant medications), and belimumab information 
(including start date, clinical response, laboratory response, side effects, and reasons for 
discontinuation of belimumab). The questionnaires were completed every three months by 
the treating physician to capture long-term clinical patterns of belimumab.
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Outcomes
All investigators adhered to the guidelines for 50% improvement as defined by the 
Responder Index for Lupus Erythematosus (RIFLE) and British Isles Lupus Assessment 
Group (BILAG), including clinical improvement and at least intent to decrease therapy (19, 
20) without worsening in any organ systems. This was further defined as the treating 
physician’s impression of a ≥50% improvement in the initial manifestation(s) being treated 
and the ability to taper existing steroid dose by at least 25% of the initial dose for those 
patients who were on steroids at initiation of belimumab. Anti-dsDNA positivity was defined 
as having an anti-dsDNA level above the normal range at the local laboratory; similarly, low 
complement was defined as having a C3 and/or C4 level below the normal range at the local 
laboratory. Laboratory response was defined as a ≥25% improvement in the levels of C3, C4, 
and/or a 25% decrease in anti-dsDNA antibody levels. Responders were those patients who 
achieved the outcome measures as defined above; non-responders were those who did not. 
Moreover, to be classified as a responder, there could be no worsening in other organ 
systems.
Data Analysis
Descriptive statistics were used to evaluate the baseline characteristics of enrolled patients 
using Graphpad Prism 6 (La Jolla, CA). Every three months, clinical and laboratory 
response data were evaluated using t-tests and chi-square tests where appropriate.
RESULTS
Demographics
A total of 195 SLE patients treated with belimumab were enrolled, most of whom were 
female (Table 1), with 29% black and 11% Hispanic. The average disease duration at 
initiation of belimumab was 11.9 ± 8.1 years among the 151 patients with data regarding the 
date of diagnosis available. Four patients were anti-nuclear antibody (ANA) negative.
Concomitant Medications
Of 195 patients, 7 adult-onset SLE patients were not taking any background SLE 
medications at the time of belimumab initiation (Table 1), while 73% were on antimalarials, 
and 74% were on corticosteroids. Of those on corticosteroids at initiation of belimumab, the 
mean daily prednisone equivalent dose was 12.2mg/day (range 5 to 50mg/day). The majority 
of patients (66%) were on immunosuppressive medications, with 21% on azathioprine and 
34% on mycophenolate mofetil. No patients were concurrently receiving cyclophosphamide 
or rituximab.
Clinical Manifestations
At initiation of belimumab, the breakdown of clinical manifestations requiring treatment is 
detailed in Table 1. The main clinical manifestations driving treatment were musculoskeletal 
and mucocutaneous. Proteinuria was present in 11% of patients at the time of initiation of 
belimumab.
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Belimumab was used off-label in 7 patients who were not on any background SLE 
medications at the time of initiation, though 4 were on daily oral corticosteroids. The clinical 
manifestations driving treatment were rash, arthritis and serositis. One patient was started on 
belimumab for constitutional symptoms.
Fifteen patients were on anti-malarial treatment alone at the time of initiation of belimumab. 
The main clinical manifestations driving treatment were rash, arthritis and serositis. Four 
patients had hematological abnormalities, and two patients had constitutional symptoms.
Response to belimumab
At three months of belimumab treatment, 52% of patients clinically responded to belimumab 
with improvement in the clinical manifestations driving initiation of belimumab (Figure 1). 
At 3 months, 61% of patients started on belimumab for arthritis, 43% of patients with rash, 
and 78% of patients with renal manifestations responded to therapy. At six months, data on 
120 patients were available for analysis and showed 51% with clinical response. Responders 
included 46% of patients with arthritis, 52% of patients with rash, and 57% of patients with 
renal manifestations. The mean daily prednisone equivalent dose of corticosteroids 
decreased to 9.3mg/day at 6 months from 12.2mg/day at baseline (p=NS).
At 3 months after initiation of belimumab, 68 of 103 patients (66%) had at least a 25% 
increase in C3 values, and 35 of 72 patients (48%) had a 25% decrease in anti-dsDNA 
values (Figure 1). This was maintained at 6 months, with 67% of patients demonstrating at 
least 25% decrease in anti-dsDNA values. No significant differences were found in either 
clinical or laboratory response rates in patients on different background immunosuppressive 
medications (data not shown).
Elderly Patients
Four patients were over 65 years of age at the time of initiation of belimumab therapy, and it 
was initiated off-label. The clinical manifestations driving treatment were arthritis in all 
patients and serositis in 2 patients. All patients were on daily oral prednisone at the time of 
initiation of therapy with a range of 3 to 11mg/day. Only one patient was on another 
immunosuppressive (mycophenolate mofetil), and no patients were on hydroxychloroquine. 
Two patients had elevated levels of anti-dsDNA antibodies, but no patients had 
hypocomplementemia. At 6 months, only one patient responded to therapy with resolution 
of arthritis and serositis and all patients remained on the same baseline dose of prednisone.
Black Patients
Data on blacks, although limited, show a similar pattern of improvement. Of 57 black 
patients, 4 were on no background medications at the start of belimumab. There were 17 
patients on corticosteroids. The major clinical manifestations for initiation of belimumab 
were arthritis, inability to taper steroids, and rash. When compared to the non-black patients 
in the cohort, black patients showed a higher clinical response rate to belimumab at 3 
months (82% vs 45%, p=0.0001). Data were available for 21 black patients on belimumab 
for 6 months; 67% responded to belimumab.
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Lupus Nephritis Patients
Twelve patients in the cohort had a history of lupus nephritis and proteinuria ≥1000mg/24 
hours at the time of initiation of belimumab. Follow-up data were available on 6 of these 
patients; 3 patients had ≥ 50% improvement in proteinuria after initiation of belimumab.
Childhood-onset SLE
A subset of 39 patients treated with belimumab were diagnosed with SLE prior to their 18th 
birthday, most of whom were female (Table 2), with a mean disease duration of 12±8 years 
at initiation of belimumab. Four patients were under 18 years of age at the time of initiation 
of belimumab therapy, and it was initiated off-label. All childhood-onset SLE patients were 
on background medications at the start of belimumab, including 82% on corticosteroids with 
a mean daily prednisone equivalent dose of 17mg, compared to 72% of adult-onset SLE 
patients on corticosteroids with a mean daily dose of 11mg (p<0.01). The main clinical 
manifestations treated in childhood-onset SLE patients were the inability to taper 
corticosteroids, musculoskeletal, and mucocutaneous. In the 4 patients under 18 years of age 
who were treated off-label, the clinical manifestations driving decision to treat were rash in 2 
patients, thrombocytopenia in 1, and inability to taper steroids in all four patients. Clinical 
improvement was detected at as early as 3 months after initiation of therapy in 41% of 
childhood-onset SLE patients. At six months of treatment with belimumab, 65% of 
childhood-onset SLE patients had clinically responded compared to 45% of adult-onset SLE 
patients (p=NS) (Figure 2). In addition, 18% of childhood-onset SLE patients on belimumab 
had at least 25% improvement in C3 levels and 44% had at least 25% decrease in anti-
dsDNA values, three months after starting belimumab (p=0.0001), and this was maintained 
at 6 months.
Moreover, six months after initiation of belimumab, the mean prednisone equivalent dose 
decreased from 17mg/day in childhood-onset SLE patients to 11mg/day. Steroids were 
discontinued in 35% of childhood-onset SLE patients 6 months after belimumab initiation, 
as compared with 11% of adult-onset SLE patients (p=0.002).
Safety
Data on adverse events and discontinuation of belimumab are presented in Table 3. No 
deaths were reported and 32 patients (16%) discontinued belimumab after an average of 
approximately nine months across all sites. The most common adverse effects and reasons 
for discontinuation of therapy were infection and lack of response to belimumab. The most 
serious infection was Group A Streptococcal bacteremia that occurred in one patient during 
the time she was on treatment with belimumab. She had also had an elective cervical lymph 
node biopsy performed 5 days prior to development of bacteremia. The lack of response to 
belimumab included patients who demonstrated no improvement and/or worsening clinical 
manifestations of disease while on belimumab, or developed new organ system involvement, 
as judged by the treating physicians.
Of note, 4 patients developed features of neuropsychiatric lupus (NPSLE) while on 
belimumab (one with stroke, one with psychosis, one with severe depression, and one with 
new-onset seizures), and 2 patients who had existing NPSLE experienced worsening of 
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disease while on belimumab (one with worsening depression, the other without specifics 
reported). There were also 3 patients who developed or experienced worsening of lupus 
nephritis over a year after initiation of therapy.
A total of 9 black patients discontinued belimumab, 2 due to exacerbation of renal disease, 2 
due to development of or worsening neuropsychiatric disease, 1 due to arthritis flare, 1 due 
to worsening myositis. Discontinuation reasons not related to lupus included 1 infusion 
reaction, 1 who lost her insurance, and 1 who self-discontinued.
DISCUSSION
Belimumab is the first FDA-approved drug for the treatment of SLE in several decades and 
marks a breakthrough in drug development in SLE (21). This study evaluates the efficacy 
and safety of belimumab in 10 large academic clinical practices, and is the first report of the 
efficacy and safety of belimumab in childhood-onset SLE.
Post-hoc analyses of the phase II belimumab trial data resulted in the development of a novel 
SLE responder index, which served as a primary endpoint in the phase III program (22); 
however, the stringency of this index precludes its practical use in routine clinical settings. 
Therefore, the definition of clinical response used in this study is a simplified version of the 
SRI; clinical response in this study was constructed around the treating physician’s 
subjective assessment of at least 50% improvement clinical manifestations, similar to the 
SLEDAI SRI-50 (23, 24). Our data suggest that clinical improvement in response to 
belimumab may be detected as early as 3 months after initiation of therapy, and 51% of 
patients show a response at 6 months. Improvements in complement and dsDNA antibody 
levels were seen as early as 3 months after initiation of belimumab therapy and continued 
through the 6-month follow-up.
Since the results of the phase III trials, post-marketing analyses have consistently 
demonstrated arthritis and mucocutaneous disease as common indications for the initiation 
of belimumab therapy (25). Interestingly, less than 5% of the cohort as a whole were on 
treatment with methotrexate prior to initiation of belimumab. Our data in a subset of patients 
with childhood-onset SLE demonstrate similar trends; however, our data also show that over 
80% of childhood-onset SLE patients were started on belimumab due to an inability to taper 
existing steroids for treatment of lupus. Childhood-onset SLE patients may respond in as 
quickly as 3 months after initiation of belimumab (41%) and a greater proportion responded 
to belimumab (65%) than adult-onset SLE patients (45%) at 6 months (p=NS). The ability to 
taper and often discontinue corticosteroids in childhood-onset SLE patients while on 
treatment with belimumab may, in part, reflect a degree of non-compliance to oral 
immunosuppressive medications in these patients.
Despite the small sample sizes in this study, serologically positive SLE patients responded 
favorably to treatment with belimumab plus standard of care therapy. This is consistent with 
the phase III belimumab trials (7, 8, 26). Moreover, given the higher prevalence of SLE in 
black patients (27, 28), it is of interest to note that 67% of a subset of black patients 
responded to belimumab therapy at 6 months. Subset analyses in phase III trials yielded 
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lower response rates of black patients receiving belimumab versus those receiving placebo. 
Our data demonstrate a better clinical response rate in blacks that is significantly higher than 
those of other racial or ethnic subsets. Thus, results from clinical trials currently underway 
focusing on black patients would be of utmost importance to individually tailor therapy.
Further studies in a larger population and for a longer time period will also be of benefit to 
examine long-term outcomes and delineate adverse events. Ginzler et al (29) recently noted 
that there was a reduced risk of SLE flare and continued improvement in clinical and 
laboratory markers 7 years after initiation of belimumab therapy. Studies in patients with 
lupus nephritis and/or NPSLE would also help define the role for belimumab and describe 
the target population for optimal response. Although NPSLE patients have been excluded 
from trials to date, there are ongoing trials using belimumab for patients with lupus nephritis 
which will provide more definitive answers.
Although data are limited, belimumab appears to be well-tolerated; 16% of patients 
experienced an adverse event. This is a much lower rate of occurrence than reported by 
Wallace et al (30) in a post-hoc analysis of the phase III trials. In the phase III trials, 6% of 
patients developed depression, and 0.1% had suicidal ideation on belimumab therapy. In our 
cohort, there were 6 patients who developed or had an exacerbation of existing NPSLE; 
belimumab was discontinued in all these patients. Wallace et al (30) also noted a small 
percentage of renal disease flare in patients on belimumab therapy. In addition, Dooley et al 
(31) demonstrated in a post-hoc analysis of the phase III trial patients that of the 267 patients 
with renal disease at the time of initiation of belimumab therapy, those on baseline 
immunosuppressive medications or with serologic activity at baseline had greater renal 
improvement on belimumab than those with placebo. They also note that renal flares and 
reduction of renal symptomatology such as proteinuria and serologic activity appeared to 
occur more frequently in patients on belimumab but was not statistically significant when 
compared with placebo. Our data show that three patients developed or had an exacerbation 
of lupus nephritis; all were childhood-onset SLE patients. However, in these patients, non-
compliance with background standard-of-care lupus immunosuppressive medications may 
have also played a role in worsening lupus nephritis.
Moreover, given that we defined the lack of response to be no improvement and/or 
worsening disease in any involved organ system, and/or development of disease in another 
previously uninvolved organ system, it is possible that the inclusion of these patients in 
calculating our response rate may reflect a lower rate of response than could be expected. 
Other limitations include the short time of follow-up (6 months) in this study, and the lack of 
comparison to a control group. This may have led us to overstate the efficacy of belimumab 
in our population.
In summary, this study further substantiates the safety and efficacy of belimumab in the 
treatment of SLE. The higher clinical response rate among black patients, with comparable 
safety, is reassuring and should help alleviate concerns regarding the use of belimumab in 
this racial group. Overall, belimumab appears to be well-tolerated; however, caution is 
advised with its use in SLE patients with active NPSLE and/or renal disease until more data 
are available. Moreover, our data suggest a larger role for belimumab as a corticosteroid-
Hui-Yuen et al. Page 8
J Rheumatol. Author manuscript; available in PMC 2016 December 01.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
sparing agent in childhood-onset SLE given that 35% of patients were able to discontinue 
steroid treatment after the addition of belimumab to standard-of-care lupus treatments. The 
results of the clinical trials currently underway in pediatric SLE patients (under 18 years of 
age) will be of interest in demonstrating the efficacy and safety of belimumab in this 
population.
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Figure 1. 
Response to belimumab in all patients with lupus at 3 and 6 months after initiation of 
belimumab. Data were available on 158 patients at 3 months and 120 patients at 6 months of 
treatment. Clinical response was defined as the treating physician’s impression of ≥50% 
improvement in the initial manifestation(s) being treated and no worsening in other organ 
systems. Improvement in serology included at least 25% decrease in anti-dsDNA level from 
baseline.
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Figure 2. 
Response to belimumab in patients with childhood-onset lupus at 3 and 6 months after 
initiation of belimumab. Data were available on 35 patients at 3 months and 26 patients at 6 
months of treatment. Clinical response was defined as the treating physician’s impression of 
≥50% improvement in the initial manifestation(s) being treated and no worsening in other 
organ systems. Improvement in serology included at least 25% decrease in anti-dsDNA level 
from baseline.
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Table 1
All lupus patients: Baseline demographics, concomitant medications, and clinical manifestations driving 
treatment with belimumab.
Baseline, n = 195
Female (%) 82
Mean age at diagnosis (range) 40.7 ± 13.7 years (4 to 65 years)
Disease duration at initiation of belimumab (n=151) 11.9 ± 8.1 years
Age at initiation of belimumab (range) 41.8 ± 12.7 years (15 to 73 years)
Race %
Caucasian 61
Black 29
Asian 6
Other 2
Ethnicity %
Hispanic/Latino 6
Clinical Manifestations %
Arthritis 67
Rash 44
Constitutional 25
Inability to Taper Steroids 30
Renal 11
Neuropsychiatric lupus 9
More than two manifestations 67
Laboratory Manifestations %
Hematologic 15
Hypocomplementemia 53
Elevated anti-dsDNA antibodies 37
Concomitant Medications %
Antimalarials 73
Prednisone 74
Mean dose prednisone equivalent 12.2mg/day (range 5 to 50mg/day)
Immunosuppressive Agents 48
 Mycophenolate 34
 Azathioprine 21
 Methotrexate 11
Angiotensin converting enzyme inhibitor 6
No SLE Medications 7
Abbreviations: anti-dsDNA, anti-double stranded DNA; SLE, systemic lupus erythematosus
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Table 2
Childhood-onset vs adult-onset lupus patients: Baseline demographics, concomitant medications, and clinical 
manifestations driving treatment with belimumab.
Baseline
Childhood-onset SLE (n=39) Adult-onset SLE (n=156)
Women (%) 90 92.3
Mean age at diagnosis 14 ± 4 years 33 ± 12 years
Disease duration at initiation of belimumab 12 ± 8 years 11 ± 7 years
Age at initiation of belimumab 27 ± 7 years * 45 ± 11 years *
Race %
Caucasian 46 65
Black 48 25
Asian 6 6
Other 0 4
Ethnicity % %
Hispanic/Latino 12 4
Clinical Manifestations % %
Arthritis 46 70
Rash 36 45
Constitutional 13 27
Inability to Taper Steroids 82 28
Renal 15 11
Neuropsychiatric lupus 0 10
Laboratory Manifestations % %
Hematologic 5 12
Hypocomplementemia 59% 52%
Elevated anti-dsDNA antibodies 84% 29%
Concomitant Medications % %
Antimalarials 92 68
Prednisone 82 * 72
Mean dose prednisone equivalent 17mg/day * 11mg/day
Immunosuppressive Agents 72 53
 Mycophenolate 49 33
 Azathioprine 23 20
 Methotrexate 0 14
Angiotensin converting enzyme inhibitor 8 4
No SLE Medications 0 4
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Table 3
Adverse events and reason(s) for discontinuation of belimumab.
Reasons for Discontinuation
Development/worsening neuropsychiatric lupus 6
Severe disease flares 4 (renal, arthritis)
Myocardial Infarction 1
Loss of Insurance 2
Infection 7 {most severe: pneumonia, Group A streptococcus bacteremia, axillary MRSA*}
Infusion Reaction 3
Elective Surgery 1
Patient Choice 2
No Clinical Response 6
Total (out of 195) 32 (16%)
Note:
*
Methicillin-Resistant Staphylococcus Aureus
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